US FDA Oks Monthly Maintenance Dosing for Eisai/Biogen's Alzheimer's Drug

2025-01-26T200333Z_2018950835_RC2F2W9MV58S_RTRMADP_3_HEALTH-USA-ALZHEIMERS
The U.S. Food and Drug Administration has approved monthly maintenance dosing for Japan’s Eisai and partner Biogen’s Alzheimer’s drug Leqembi, the companies said on Monday.

New contents